Quarterly Result19 May 2026, 07:31 pm
Mankind Pharma Approves Audited FY26 Financial Results
AI Summary
Mankind Pharma Ltd's Board of Directors approved the audited standalone and consolidated financial results for the quarter and financial year ended March 31, 2026. The board also approved the realignment of security cover for Non-Convertible Debentures post redemption, re-appointed Mr. Satish Kumar Sharma as Whole-Time Director, and re-appointed M/s. M. K. Kulshrestha & Associates as Cost Auditors for FY27. Additionally, the board took note of the resignation of Mr. Pramod Gokhale, Global Chief Information Officer, and approved an additional investment of up to ₹500 crores in Mankind Medicare Private Limited.
Key Highlights
- Audited financial results for FY26 approved by the board.
- Re-appointment of Mr. Satish Kumar Sharma as Whole-Time Director approved.
- Mankind to invest up to ₹500 crores in Mankind Medicare Private Limited.
- Mr. Pramod Gokhale resigned as Global Chief Information Officer.
- Executive Directors forgo commission to strengthen company's cash position.
Price Impact
More from MANKIND